Top

Breast Cancer Research and Treatment

Published in:

01-01-2011 | Letter to the Editor

No significant association results obtained from significant association evidence: the ongoing uncertainty of TP53 codon 72 polymorphism and breast cancer risk

Authors: Pei-Hua Lu, Guo-Qing Tao, Xiao Liu, Chen Li, Mu-Xin Wei

Published in: Breast Cancer Research and Treatment | Issue 2/2011

Excerpt

To the Editor, …

Ma Y, Yang J, Liu Z, Zhang P, Yang Z, Wang Y, Qin H (2010) No significant association between the TP53 codon 72 polymorphism and breast cancer risk: a meta-analysis of 21 studies involving 24,063 subjects. Breast Cancer Res Treat. (Epub ahead)

Kawajiri K, Nakachi K, Imai K, Watanabe J, Hayashi S (1993) Germ line polymorphisms of p53 and CYP1A1 genes involved in human lung cancer. Carcinogenesis 14:1085–1089CrossRefPubMed

Noma C, Miyoshi Y, Taguchi T, Tamaki Y, Noguchi S (2004) Association of p53 genetic polymorphism (Arg72Pro) with estrogen receptor positive breast cancer risk in Japanese women. Cancer Lett 210:197–203CrossRefPubMed

Ma H, Hu Z, Zhai X, Wang S, Wang X, Qin J, Chen W, Jin G, Liu J, Gao J et al (2006) Joint effects of single nucleotide polymorphisms in P53BP1 and p53 on breast cancer risk in a Chinese population. Carcinogenesis 27:766–771CrossRefPubMed

Singh V, Rastogi N, Mathur N, Singh K, Singh MP (2008) Association of polymorphism in MDM-2 and p53 genes with breast cancer risk in Indian women. Ann Epidemiol 18:48–57CrossRefPubMed

Rajkumar T, Samson M, Rama R, Sridevi V, Mahji U, Swaminathan R, Nancy NK (2008) TGFbeta1 (Leu10Pro), p53 (Arg72Pro) can predict for increased risk for breast cancer in south Indian women and TGFbeta1 Pro (Leu10Pro) allele predicts response to neo-adjuvant chemo-radiotherapy. Breast Cancer Res Treat 112:81–87CrossRefPubMed

Papadakis EN, Dokianakis DN, Spandidos DA (2000) p53 codon 72 polymorphism as a risk factor in the development of breast cancer. Mol Cell Biol Res Commun 3:389–392CrossRefPubMed

Ohayon T, Gershoni-Baruch R, Papa MZ, Distelman MT, Eisenberg BS, Friedman E (2005) The R72P P53 mutation is associated with familial breast cancer in Jewish women. Br J Cancer 92:1144–1148CrossRefPubMed

Suspitsin EN, Buslov KG, Grigoriev MY, Ishutkina JG, Ulibina JM, Gorodinskaya VM, Pozharisski KM, Berstein LM, Hanson KP, Togo AV et al (2003) Evidence against involvement of p53 polymorphism in breast cancer predisposition. Int J Cancer 103:431–433CrossRefPubMed

10.

Menzel HJ, Sarmanova J, Soucek P, Berberich R, Grunewald K, Haun M, Kraft HG (2004) Association of NQO1 polymorphism with spontaneous breast cancer in two independent populations. Br J Cancer 90:1989–1994CrossRefPubMed

11.

Garcia-Closas M, Kristensen V, Langerod A, Qi Y, Yeager M, Burdett L, Welch R, Lissowska J, Peplonska B, Brinton L et al (2007) Common genetic variation in TP53 and its flanking genes, WDR79 and ATP1B2, and susceptibility to breast cancer. Int J Cancer 121:2532–2538CrossRefPubMed

12.

Johnson N, Fletcher O, Palles C, Rudd M, Webb E, Sellick G, dos SSI, McCormack V, Gibson L, Fraser A et al (2007) Counting potentially functional variants in BRCA1, BRCA2 and ATM predicts breast cancer susceptibility. Hum Mol Genet 16:1051–1057CrossRefPubMed

13.

Baynes C, Healey CS, Pooley KA, Scollen S, Luben RN, Thompson DJ, Pharoah PD, Easton DF, Ponder BA, Dunning AM (2007) Common variants in the ATM, BRCA1, BRCA2, CHEK2 and TP53 cancer susceptibility genes are unlikely to increase breast cancer risk. Breast Cancer Res 9:R27CrossRefPubMed

14.

Costa S, Pinto D, Pereira D, Rodrigues H, Cameselle-Teijeiro J, Medeiros R, Schmitt F (2008) Importance of TP53 codon 72 and intron 3 duplication 16 bp polymorphisms in prediction of susceptibility on breast cancer. BMC Cancer 8:32CrossRefPubMed

15.

Cox DG, Deer D, Guo Q, Tworoger SS, Hankinson SE, Hunter DJ, De Vivo I (2007) The p53 Arg72Pro and MDM2–309 polymorphisms and risk of breast cancer in the nurses’ health studies. Cancer Causes Control 18:621–625CrossRefPubMed

16.

Gaudet MM, Gammon MD, Bensen JT, Sagiv SK, Shantakumar S, Teitelbaum SL, Eng SM, Neugut AI, Santella RM (2008) Genetic variation of TP53, polycyclic aromatic hydrocarbon-related exposures, and breast cancer risk among women on Long Island, New York. Breast Cancer Res Treat 108:93–99CrossRefPubMed

Title: No significant association results obtained from significant association evidence: the ongoing uncertainty of TP53 codon 72 polymorphism and breast cancer risk
Authors: Pei-Hua Lu
Guo-Qing Tao
Xiao Liu
Chen Li
Mu-Xin Wei
Publication date: 01-01-2011
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 2/2011
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-010-1220-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 2/2011

Association of age and overall survival in capecitabine-treated patients with metastatic breast cancer in clinical trials

The impact of an aromatase inhibitor on body composition and gonadal hormone levels in women with breast cancer

Vascular endothelial growth factor receptor 2 and downstream p38 mitogen-activated protein kinase are possible candidate markers of intrinsic resistance to adjuvant endocrine treatment in steroid receptor positive breast cancer

Lack of association between ATM C.1066-6T > G mutation and breast cancer risk: a meta-analysis of 8,831 cases and 4,957 controls

Targeting mutant p53 protein and the tumor vasculature: an effective combination therapy for advanced breast tumors

HER2 status in a population-derived breast cancer cohort: discordances during tumor progression

Keynote webinar | Spotlight on antibody–drug conjugates in cancer